Skip to main content
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. — Investor Relations & Filings

Ticker · STOK ISIN · US86150R1077 LEI · 549300RD25SS2DIJHJ67 US Manufacturing
Open in API
Filings indexed 559 across all filing types
Latest filing 2019-06-13 Regulatory Filings
Country US United States of America
Listing US STOK

About Stoke Therapeutics, Inc.

https://www.stoketherapeutics.com/

Stoke Therapeutics, Inc. is a biotechnology company focused on developing treatments for severe genetic diseases by addressing their underlying cause. The company utilizes its proprietary research platform, TANGO (Targeted Augmentation of Nuclear Gene Output), an RNA-based approach designed to restore protein levels. This technology works by upregulating protein expression from the healthy copy of a gene to compensate for a mutated or non-functioning copy, a mechanism particularly suited for haploinsufficient diseases. Stoke's lead investigational medicine, zorevunersen (STK-001), is in late-stage clinical development for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company is also advancing its platform to treat other genetic conditions, including autosomal dominant optic atrophy (ADOA).

Recent filings

Filing Released Lang Actions
Regulatory Filings 2019
Regulatory Filings
2019-06-13 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter from legal counsel responding to comments from the SEC staff regarding an Amendment No. 1 to a Registration Statement on Form S-1 filed by Stoke Therapeutics, Inc. It discusses revisions made to the Registration Statement and references Amendment No. 2 filed subsequently. The content is focused on regulatory correspondence related to a securities registration filing, specifically a Form S-1, which is used for initial public offerings and related disclosures. The document is not a financial report, earnings release, or management discussion, but rather a regulatory correspondence addressing SEC comments and amendments to a registration statement. Given the nature of the document as a response letter to SEC comments on a registration filing, it fits best under Regulatory Filings (RNS). The document length is under 5,000 characters and it is a letter, not the registration statement itself or a report publication announcement.
2019-06-12 English
S-1/A
Regulatory Filings Classification · 100% confidence The document is an S-1/A Registration Statement Amendment No. 2 filed with the SEC on June 12, 2019, for Stoke Therapeutics, Inc. It is a detailed registration statement under the Securities Act of 1933, used for initial public offerings (IPOs). The text includes a prospectus summary, risk factors, use of proceeds, capitalization, dilution, selected consolidated financial data, management's discussion and analysis, business description, management, executive compensation, principal stockholders, and other sections typical of an S-1 filing. This is not an earnings release, annual report, or any other type of report but a registration statement for securities offering. According to the filing definitions, this type of document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into other specific categories like capital/financing update or proxy solicitation. The document is lengthy (15,000 characters) and contains substantive information, but it is not a financial report or presentation; it is a registration statement filing with the SEC.
2019-06-12 English
8-A12B
Regulatory Filings Classification · 95% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. It includes details about the registration of common stock on Nasdaq and references the related S-1 registration statement. The document is a regulatory filing related to securities registration, not a financial report, earnings release, or other types of filings. It is a formal regulatory announcement of securities registration, which fits best under the category of Regulatory Filings (RNS). The document length is 3342 characters, which is relatively short and consistent with a regulatory filing form rather than a full report.
2019-06-11 English
Regulatory Filings 2019
Regulatory Filings Classification · 80% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, form names, fiscal period dates, or document titles that can be used to identify the filing type. The text is approximately 15,000 characters long, which is substantial, but without any meaningful content or context, it is impossible to classify it as a specific report or announcement. Given the lack of identifiable information and the fallback rule for documents that do not fit any specific category, the appropriate classification is Regulatory Filings (RNS).
2019-06-11 English
Regulatory Filings 2019
Regulatory Filings Classification · 100% confidence The document is a response letter from a company's legal counsel to the SEC staff regarding comments on a Registration Statement on Form S-1. It discusses amendments to the Registration Statement and addresses SEC staff comments. The document does not contain financial statements or detailed financial data but is a correspondence related to a regulatory filing. It is not the Registration Statement itself but a letter responding to SEC comments on it. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements, compliance documents, and correspondence with regulators that do not fit other categories.
2019-06-07 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.